Sangamo Therapeutics, Inc. (0R1D.L)
USD 2.62
(-3.68%)
USD 2.62
(-3.68%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 33.51 Million USD | -14.03% |
| 2022 | 38.98 Million USD | -11.51% |
| 2021 | 44.05 Million USD | 14.74% |
| 2020 | 38.39 Million USD | -6.79% |
| 2019 | 41.19 Million USD | 48.77% |
| 2018 | 27.68 Million USD | 11.93% |
| 2017 | 24.73 Million USD | 527.07% |
| 2016 | 3.94 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 300 Thousand USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 29.09 Million USD | 0.0% |
| 2024 Q1 | 30.81 Million USD | 0.0% |
| 2023 Q2 | 36.37 Million USD | -3.52% |
| 2023 FY | 33.51 Million USD | -14.03% |
| 2023 Q4 | 33.51 Million USD | -4.17% |
| 2023 Q1 | 37.7 Million USD | -3.3% |
| 2023 Q3 | 34.97 Million USD | -3.84% |
| 2022 FY | 38.98 Million USD | -11.51% |
| 2022 Q2 | 41.53 Million USD | -3.0% |
| 2022 Q1 | 42.81 Million USD | -2.81% |
| 2022 Q3 | 39.7 Million USD | -4.39% |
| 2022 Q4 | 38.98 Million USD | -1.81% |
| 2021 Q2 | 37.32 Million USD | -2.95% |
| 2021 Q1 | 38.46 Million USD | 0.17% |
| 2021 FY | 44.05 Million USD | 14.74% |
| 2021 Q4 | 44.05 Million USD | 21.97% |
| 2021 Q3 | 36.12 Million USD | -3.23% |
| 2020 Q1 | 40.19 Million USD | -2.41% |
| 2020 Q3 | 38.25 Million USD | -2.49% |
| 2020 Q4 | 38.39 Million USD | 0.36% |
| 2020 FY | 38.39 Million USD | -6.79% |
| 2020 Q2 | 39.23 Million USD | -2.4% |
| 2019 Q4 | 41.19 Million USD | 1.44% |
| 2019 Q3 | 40.6 Million USD | -2.26% |
| 2019 Q2 | 41.55 Million USD | 212.43% |
| 2019 Q1 | 13.29 Million USD | -51.97% |
| 2019 FY | 41.19 Million USD | 48.77% |
| 2018 Q4 | 27.68 Million USD | 2.83% |
| 2018 FY | 27.68 Million USD | 11.93% |
| 2018 Q3 | 26.92 Million USD | 2.86% |
| 2018 Q2 | 26.18 Million USD | 2.87% |
| 2018 Q1 | 25.44 Million USD | 2.87% |
| 2017 Q3 | 3.87 Million USD | -0.44% |
| 2017 Q2 | 3.88 Million USD | -1.04% |
| 2017 Q4 | 24.73 Million USD | 539.22% |
| 2017 FY | 24.73 Million USD | 527.07% |
| 2017 Q1 | 3.92 Million USD | -0.43% |
| 2016 Q2 | 247 Thousand USD | 15.96% |
| 2016 FY | 3.94 Million USD | 0.0% |
| 2016 Q4 | 3.94 Million USD | 74.87% |
| 2016 Q3 | 2.25 Million USD | 813.36% |
| 2016 Q1 | 213 Thousand USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q1 | 12.61 Million USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q2 | - USD | -100.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 FY | 300 Thousand USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -37.514% |
| Dynavax Technologies Corporation | 252.41 Million USD | 86.722% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -0.961% |
| Perrigo Company plc | 3.63 Billion USD | 99.077% |
| Illumina, Inc. | 1.48 Billion USD | 97.749% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.893% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3251.5% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.583% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.741% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 80.711% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.76% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -42.381% |
| Waters Corporation | 2.3 Billion USD | 98.546% |
| Biogen Inc. | 7.18 Billion USD | 99.534% |
| Evolus, Inc. | 120.35 Million USD | 72.154% |
| Adicet Bio, Inc. | 17.7 Million USD | -89.318% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 9.612% |
| bluebird bio, Inc. | 224.41 Million USD | 85.066% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 93.318% |
| FibroGen, Inc. | 89.69 Million USD | 62.635% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.775% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -934.851% |
| Homology Medicines, Inc. | 43.17 Million USD | 22.376% |
| Geron Corporation | 35.05 Million USD | 4.382% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.57% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 91.359% |
| Myriad Genetics, Inc. | 130.9 Million USD | 74.396% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -3480.662% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 65.358% |
| Zoetis Inc. | 6.56 Billion USD | 99.489% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -661.358% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.304% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 94.349% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 95.375% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 1.974% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 97.607% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 26.652% |
| Verastem, Inc. | 40.08 Million USD | 16.392% |
| Nektar Therapeutics | 112.62 Million USD | 70.242% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 81.179% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -990.273% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 97.041% |
| OPKO Health, Inc. | 222.03 Million USD | 84.905% |
| Exelixis, Inc. | 189.94 Million USD | 82.355% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 87.025% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | 74.232% |
| Imunon, Inc. | 1.13 Million USD | -2841.737% |
| Blueprint Medicines Corporation | 610.96 Million USD | 94.514% |
| Insmed Incorporated | 1.19 Billion USD | 97.192% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.765% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 41.189% |
| TG Therapeutics, Inc. | 100.11 Million USD | 66.525% |
| Incyte Corporation | 29.16 Million USD | -14.927% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 92.494% |